Related references
Note: Only part of the references are listed.Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial
Michel Zeitouni et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review
Tim A. C. de Vries et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
Ken Okumura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
Hee Tae Yu et al.
KOREAN CIRCULATION JOURNAL (2020)
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function
So-Ryoung Lee et al.
STROKE (2019)
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation
Yi-Hsin Chan et al.
CHEST (2019)
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
So-Ryoung Lee et al.
SCIENTIFIC REPORTS (2019)
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation
So-Ryoung Lee et al.
STROKE (2019)
Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation
Jiesuck Park et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
So-Ryoung Lee et al.
YONSEI MEDICAL JOURNAL (2019)
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
Marco Proietti et al.
STROKE (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report
Gregory Y. H. Lip et al.
CHEST (2018)
Edoxaban in Asian Patients With Atrial Fibrillation Effectiveness and Safety
So-Ryoung Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan
Tze-Fan Chao et al.
CIRCULATION (2018)
2018 Korean Guideline of Atrial Fibrillation Management
Boyoung Joung et al.
KOREAN CIRCULATION JOURNAL (2018)
The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2
Menno V. Huisman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
Xiaoxi Yao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
Chao-Lun Lai et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes The ORBIT-AF II Registry
Benjamin A. Steinberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation
David J. Graham et al.
JAMA INTERNAL MEDICINE (2016)
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine
John H. Alexander et al.
JAMA CARDIOLOGY (2016)
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
Gregory Y. H. Lip et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
Peter C. Austin et al.
STATISTICS IN MEDICINE (2015)
Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation Meta-Analysis
Kang-Ling Wang et al.
STROKE (2015)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation - The J-ROCKET AF Study
Masatsugu Hori et al.
CIRCULATION JOURNAL (2012)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
Lars Wallentin et al.
LANCET (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation
Albert Yuh-Jer Shen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Share Paper
